WO2020218432A1 - キノリンカルボキサミド誘導体を用いる免疫チェックポイント阻害剤併用療法 - Google Patents
キノリンカルボキサミド誘導体を用いる免疫チェックポイント阻害剤併用療法 Download PDFInfo
- Publication number
- WO2020218432A1 WO2020218432A1 PCT/JP2020/017522 JP2020017522W WO2020218432A1 WO 2020218432 A1 WO2020218432 A1 WO 2020218432A1 JP 2020017522 W JP2020017522 W JP 2020017522W WO 2020218432 A1 WO2020218432 A1 WO 2020218432A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- group
- substituted
- formula
- immune checkpoint
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Definitions
- the present invention relates to cancer combination therapy using a quinoline carboxamide derivative.
- STAT Signal Transducers and Activators of Transcription
- IL-6 cytokines
- EGF growth factor
- PDGF growth factor
- the STATs that are activated by forming dimers translocate into the nucleus, specifically recognize and bind to specific DNA sequences in the gene promoter region, and induce transcription of many genes. That is, STAT is an essential mediator in the pathway of transmitting signals from the cell surface to the nucleus, and is deeply involved in cell proliferation and differentiation.
- STAT3 Seven different members of STAT are known, of which STAT3 is expressed in most cell types, the constitutive activation and overexpression of which is in lung cancer, skin cancer and pancreas. It is found in cancer cells such as ovarian cancer, myeloma, breast cancer, prostate cancer, brain cancer, head and neck cancer, melanoma, leukemia lymphoma and multiple myeloma, and these cancer cells Proliferation and infiltration are believed to be STAT3 dependent.
- STAT3 is considered to be useful as a target molecule for these cancer types, and its inhibitor is expected as an anticancer agent.
- a specific quinoline carboxamide derivative has excellent STAT3 inhibitory activity and has antitumor activity against various cancers (Patent Document 1).
- cancer cells contain various immune checkpoint molecules that interfere with the immune response to cancer.
- Immune checkpoint inhibition is a new therapeutic method that releases the immunosuppressive mechanism and activates the immune response against cancer.
- anti-CTLA-4 cytotoxic T lymphoactive antibody-4
- Antibodies ipilimumab, anti-PD-1 (programmed cell death-1) antibodies nivolumab, pembrolizumab, and the like are used in Japan and overseas.
- the present invention relates to providing a method for using a quinoline carboxamide derivative that exhibits an excellent antitumor effect.
- the present inventors orally pre-administer the quinoline carboxamide derivative and then administer an immune checkpoint inhibitor. It was found that an excellent antitumor effect can be obtained by the combined administration.
- the present invention relates to the following inventions 1) to 19).
- the quinoline carboxamide derivative represented by the formula (I) is N- [5- (2-furyl) -1,3,4-oxadiazole-2-yl] -2-phenyl-6-trifluoromethoxy- 4-quinoline carboxamide, an antitumor agent according to any one of 1) to 11).
- Immune checkpoint inhibitors are selected from CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM3, BTLA, B7H3, B7H4, 2B4, CD160, A2aR, KIR, VISTA and TIGIT.
- An antitumor agent according to any one of 1) to 12) which is a substance that acts on an immune checkpoint molecule to suppress the checkpoint function.
- the PD-1 pathway inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.
- Cancers are non-small cell lung cancer, renal cell cancer, Hodgkin lymphoma, head and neck cancer, gastric cancer, malignant pleural mesenteric tumor, esophageal cancer, gastroesophageal junction cancer, small cell cancer, glue bud Tumor, urinary tract epithelial cancer, muscular layer invasive urinary tract epithelial cancer, bladder cancer, muscle layer non-invasive bladder cancer, colon cancer, pancreatic cancer, prostate cancer, merkel cell cancer, thyroid cancer , Hepatocyte cancer, breast cancer, ovarian cancer, uterine body cancer, cervical cancer, soft sarcoma, virus positive / negative solid cancer, central nervous system primary lymphoma / testis primary lymphoma, MSI-High solid cancer, melanoma And one or more antitumor agents selected from 1) to 15) selected from leukemia.
- An antitumor agent administered in combination with an immune checkpoint inhibitor which is administered before administration of the immune checkpoint inhibitor, and is represented by the following formula (I) for producing an antitumor agent.
- Use of quinoline carboxamide derivatives or salts thereof Use of quinoline carboxamide derivatives or salts thereof.
- a quinoline carboxamide derivative represented by the following formula (I) or a salt thereof which is used in combination with an immune checkpoint inhibitor for cancer treatment and is administered before administration of the immune checkpoint inhibitor.
- a method for treating cancer which comprises administering an effective amount of a quinoline carboxamide derivative represented by the following formula (I) or a salt thereof and an immune checkpoint inhibitor to a patient, wherein the quinoline carboxamide derivative or a salt thereof is used.
- R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are the same or different, hydrogen atom, substituted or unsubstituted aryl group, substituted or unsubstituted aromatic heterocyclic group, COOR 7 (In the formula, R 7 indicates a substituted or unsubstituted alkyl group) or OR 8 (in the formula, R 8 indicates a substituted or unsubstituted alkyl group). ]
- the antitumor agent of the present invention it is possible to perform cancer treatment having a high antitumor effect, and thus bring about long-term survival of the patient. Further, since the quinoline carboxamide derivative of the present invention can be orally administered and is effective against a wide range of cancer types, it can exert a combined effect on at least any cancer for which an immune checkpoint inhibitor is effective. ..
- Antitumor effect in combination with STX-1159 and anti-PD-1 antibody Antitumor effect in combination with STX-1159 and anti-PD-1 antibody. Antitumor effect in combination with STX-1159 and anti-PD-1 antibody.
- R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are the same or different, and hydrogen.
- substituent in the alkyl group include a halogen atom and a hydroxy group.
- Examples of the substituent in the aryl group and the aromatic heterocyclic group include an alkyl group having 1 to 6 carbon atoms, an alkenyl group, an alkynyl group, a cycloalkyl group, an aralkyl group, OR a , NR b R c and S (O).
- Ra to R w may represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, or the like, which may be the same or different.
- the number of substitutions of these substituents may be the same or different, up to the maximum number of hydrogen atoms present in each group, but is preferably 1 to 10, and more preferably 1 to 5.
- each group defined in the above general formula (I) Details of each group defined in the above general formula (I) are shown below.
- a group in which a positional isomer is present in each group represents all possible positional isomers.
- Examples of the alkyl moiety of the alkyl group and the alkoxy group include linear or branched alkyl having 1 to 12 carbon atoms, specifically, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-.
- Examples thereof include butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like.
- cycloalkyl group examples include a 3- to 12-membered cycloalkyl group in which a saturated or partially unsaturated bond may be present, and the monocyclic or monocyclic cycloalkyl group is plural, an aryl group, or an aromatic group. It may be a polycyclic condensed cycloalkyl group fused with a group heterocyclic group.
- Examples of the monocyclic cycloalkyl group include monocyclic cycloalkyl having 3 to 8 carbon atoms, specifically, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclododecyl, 1-cyclo. Examples thereof include hexenyl and the like, and examples of the polycyclic cycloalkyl group include polycyclic cycloalkyl having 5 to 12 carbon atoms, specifically, pinanyl, adamantyl, bicyclo [3.3.1] octyl and bicyclo. [3.1.1] Heptyl and the like can be mentioned.
- alkenyl group examples include linear or branched alkenyl having 2 to 12 carbon atoms, specifically, vinyl, allyl, 1-propenyl, isopropenyl, methacrylic, butenyl, 1,3-butadienyl, crotyl, and pentenyl. , Hexenyl, heptenyl, decenyl, dodecenyl and the like.
- alkynyl group examples include linear or branched alkynyl having 2 to 12 carbon atoms, specifically, ethynyl, propargyl, 1-propynyl, isopropynyl, 2-butynyl, pentynyl, 2-penten-4-inyl. , Hexinyl, heptinyl, decynyl, dodecynyl and the like.
- aryl group examples include aryls having 6 to 14 carbon atoms, specifically, phenyl, naphthyl, anthryl, phenanthryl and the like.
- the aromatic heterocyclic group is the same or different and consists of a 5- or 6-membered aromatic heterocyclic group containing at least one or more different atoms, for example, nitrogen, oxygen, sulfur, etc., and the heterocyclic group is composed of a 5- or 6-membered aromatic heterocyclic group.
- Monocyclic or a polycyclic condensed aromatic heterocyclic group in which the monocyclic heterocyclic group is condensed with a plurality of or aryl groups, for example, a bicyclic or tricyclic heterocyclic group may be used.
- monocyclic aromatic heterocyclic groups include frills, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl.
- polycyclic condensed aromatic heterocyclic group examples include benzofuryl, benzothienyl, indolyl, isoindrill, indazolyl, benzoimidazolyl, benzotriazolyl, benzoxazolyl, benzothiazolyl, carbazolyl, prynyl, quinolyl, isoquinolyl.
- halogen atoms include fluorine, chlorine, bromine, and iodine atoms.
- R 1 and R 2 are the same or different and are a substituted or unsubstituted aryl group or a substituted or unsubstituted aromatic heterocyclic group are preferable, and specific examples of the aryl group include A phenyl group or a naphthyl group is preferably exemplified, and a frill group or a thienyl group or the like is preferably exemplified as the aromatic heterocyclic group.
- R 1 is a frill group and R 2 is a substituted or unsubstituted phenyl group, a substituted or unsubstituted frill group or a substituted or unsubstituted thienyl group is more preferable, and the substituent of the substituted phenyl group is methyl.
- Alkyl groups such as groups, substituted or unsubstituted alkoxy groups such as methoxy groups and difluoromethoxy groups, halogen atoms such as fluorine atoms and chlorine atoms, hydroxy groups, alkoxycarbonyl groups such as tert-butoxycarbonyl, amino groups, nitro groups, A cyano group and the like are preferably exemplified, and as the substituent of the substituted frill group and the substituted thienyl group, an alkyl group such as a methyl group, a halogen atom such as a chlorine atom and the like are preferably exemplified. Furthermore, compounds in which R 3 , R 5 and R 6 are hydrogen atoms and R 4 is OR 8 (preferably a methoxy group or a trifluoromethoxy group) are more preferable.
- quinoline carboxamide derivative of the present invention examples include N- [5- (2-furyl) -1,3,4-oxadiazole-2-yl] -2-phenyl-4-quinolincarboxamide, N. -[5- (3-Frill) -1,3,4-oxadiazole-2-yl] -2-phenyl-4-quinolincarboxamide, 2-phenyl-N- (5-phenyl-1,3,4 -Oxadiazole-2-yl) -4-quinolincarboxamide, N- [5- (4-chlorophenyl) -1,3,4-oxadiazole-2-yl] -2-phenyl-4-quinolincarboxamide, N- [5- (4-nitrophenyl) -1,3,4-oxadiazole-2-yl] -2-phenyl-4-quinolincarboxamide, 2-phenyl-N- [5- (3-pyridyl) -1,3,4-oxadiazole
- Examples of the salt of the quinoline carboxamide derivative of the present invention include pharmacologically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like.
- the pharmacologically acceptable acid addition salts include inorganic acid salts such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitrate, phosphoric acid and boric acid, and formic acids such as formic acid, acetic acid, propionic acid and fumal.
- each alkali metal salt such as lithium, sodium and potassium, each alkaline earth metal salt such as magnesium and calcium, and each metal salt such as aluminum and zinc are pharmacologically acceptable.
- each salt such as ammonium and tetramethylammonium is pharmacologically acceptable
- each salt such as triethylamine, piperidine, morpholine and toluidine is pharmacologically acceptable.
- the amino acid addition salt to be added include addition salts of lysine, glycine, phenylalanine and the like.
- the quinoline carboxamide derivative of the present invention or a salt thereof is described as a STAT3 inhibitor in Japanese Patent No. 5650529 (Patent Document 1), and can be produced by the method described in the same publication.
- the quinoline carboxamide derivative or a salt thereof is known to inhibit the dimer formation of STAT3 and exert an antitumor effect.
- the immune checkpoint inhibitor used in the present invention means a substance capable of suppressing the function of a checkpoint by acting on an immune checkpoint molecule, which is a molecule that exerts an immunosuppressive function by transmitting an inhibitory co-signal. ..
- immune checkpoint molecules include PD-1, CTLA-4, OX-40, TIM3 (T cell immunoglobulin and mucin-3), LAG-3 (Lymphocyte activation gene 3), and VISTA (V-domine Ig-cotin).
- T cell activation GITR (Glucocorticoid-induced TNFR-related protein), 4-1BB, CD40, ICOS, CD28, TIGIT (T cell immunoglobulin T cell Incorporated ITIM), T cell immunoglobulin T cell , PD-L1 (prommed cell death-ligand 1), PD-L2 (programmed cell death-ligand 2), CD86, OX40L, Galectin-9 / HMGB1, GITRL, 4-1BBL, CD40L, ICSOL, CD80 , HVEM, B7H3, B7H4, 2B4, A2aR (adenosine A2a acceptor), KIR (killer indicator) and the like.
- GITR Glucocorticoid-induced TNFR-related protein
- 4-1BB CD40
- ICOS CD28
- TIGIT T cell immunoglobulin T cell Incorporated ITIM
- T cell immunoglobulin T cell PD-L1 (prommed cell death-
- Such an immune checkpoint inhibitor is preferably an inhibitor of a human immune checkpoint molecule, and more preferably a neutralizing antibody against a human immune checkpoint molecule.
- Immune checkpoint inhibitors include, for example, anti-CTLA-4 antibodies (eg, Ipilimumab (YERVOY®), Tremerimumab, AGEN-1884); anti-PD-1 antibodies (eg, nivolumab (Opdivo®)).
- anti-CTLA-4 antibodies eg, Ipilimumab (YERVOY®), Tremerimumab, AGEN-1884
- anti-PD-1 antibodies eg, nivolumab (Opdivo®)
- anti-PD-L2 antibody eg, rHIgM12B7
- PD-1 inhibitor eg, AUNP-12
- PD-L1 fusion protein eg, PD-L2 fusion protein
- PD-L2 fusion protein eg, AMP-224
- anti Tim-3 antibody eg, MBG453
- anti-LAG-3 antibody eg, BMS-986016, LAG525
- anti-KIR antibody eg, Lililimumab
- anti-OX-40 antibody eg, GSK317949, PF-04518600
- anti VISTA antibody eg, IGN-381
- anti-GITR antibody BMS-986156
- anti-4-1BB antibody eg, Utomilumab
- Antibodies containing the heavy and light chain complementarity determining regions (CDRs) or variable regions (VR) of the above-mentioned known antibodies are also included in the immune checkpoint inhibitors of the present invention.
- the antibody may be a functional antibody fragment, and examples of such antibody fragment include Fab, Fab', F (ab') 2, Fv, scFv, dsFv and the like.
- the immune checkpoint inhibitor of the present invention preferably includes anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, PD-1 inhibitor, PD-L1 fusion protein, PD-L2 fusion protein and the like.
- PD-1 pathway inhibitor that inhibits the PD-1 / PD-1 ligand pathway, and anti-CTLA-4 antibody, more preferably PD-1 pathway inhibitor, and more preferably anti-PD-1 antibody. It is an anti-PD-L1 antibody and an anti-PD-L2 antibody, and particularly preferably an anti-PD-1 antibody.
- the quinoline carboxamide derivative of the present invention or a salt thereof is administered in combination with an immune checkpoint inhibitor, it is remarkable to administer the quinoline carboxamide derivative or a salt thereof before administration of the immune checkpoint inhibitor. It exerts an excellent antitumor effect.
- a quinoline carboxamide derivative or a salt thereof this is a preferable state for the immune checkpoint inhibitor to exert its effect on the immune environment of the tumor, that is, a state in which tumor immune cells are activated, tumor immunity. This is thought to be because the restrained environment can be adjusted to a released state.
- quinoline carboxamide derivative of the present invention is an antitumor agent to be administered in combination with an immune checkpoint inhibitor, and is administered before administration of the immune checkpoint inhibitor. Can be.
- the quinoline carboxamide derivative of the present invention or a salt thereof is an antitumor agent to be administered in combination with an immune checkpoint inhibitor, and produces an antitumor agent to be administered before administration of the immune checkpoint inhibitor. Can be used for.
- “Combination administration” means that the quinoline carboxamide derivative of the present invention or a salt thereof is administered in combination within a certain period of time, but in the present invention, the order of administration is quinoline. It is necessary that the administration of the carboxamide derivative or its salt is performed before the administration of the immune checkpoint inhibitor, preferably the start of administration of the quinoline carboxamide derivative or its salt is at least 1 day before the administration of the immune checkpoint inhibitor. Is.
- the administration start time of the quinoline carboxamide derivative of the present invention or a salt thereof is more preferably 2 days or more before the administration of the immune checkpoint inhibitor, more preferably 28 to 2 days before the administration, and more preferably 21 of the administration.
- administration of the quinoline carboxamide derivative of the present invention or a salt thereof may be started before administration of the immune checkpoint inhibitor, may be continued even after the start of administration of the immune checkpoint inhibitor, and immunity.
- the administration of the checkpoint inhibitor may be terminated or suspended before the administration of the inhibitor.
- the cancer that can be treated by the antitumor agent of the present invention is not particularly limited, and is, for example, malignant neoplasm; cancer; undifferentiated cancer; giant cell and spindle cell cancer; small cell cancer; papillary cancer; squamous epithelial cancer.
- Lymph epithelial cancer Basal cell carcinoma; Mineralized epithelial cancer; Transitional epithelial cancer; Papillary transitional epithelial cancer; Adenocarcinoma; Malignant gastrinoma; Biliary tract cancer; Hepatocyte cancer; Mixed hepatocellular carcinoma and bile duct cancer; Cordoid gland Cancer; Glandular cystic carcinoma; Adenocarcinoma in adenomatous polyps; Familiar colon polyposis adenocarcinoma; Solid tumor; Malignant cartinoid tumor; Branchiolo-alveolar adenocarcinoma; Papillary adenocarcinoma; Eryophilic cancer; Eosophilic adenocarcinoma; Ebasophocytic cancer; Clear cell adenocarcinoma; Granular cell carcinoma; Follicular adenocarcinoma; Papillary and follicular adenocarcinoma; Non-encapsulating sclerosing carcinoma; Adrenal cortex cancer
- the quinoline carboxamide derivative of the present invention or a salt thereof is non-peptide and non-nucleic acid, it can be orally administered, and the above-mentioned combined effect can be effectively exhibited by oral administration.
- the advantages of oral administration are that it is not invasive and that it enables outpatient treatment, which is highly convenient for patients.
- oral administration has no effect because it is not absorbed, and the method by oral administration is very difficult. That is, the administration form of the quinoline carboxamide derivative of the present invention or a salt thereof is not particularly limited and includes oral or parenteral administration.
- parenteral administration includes intranasal, transbronchial, intramuscular, and percutaneous administration
- parenteral preparations include injections (intravenous injection such as infusion, subcutaneous injection). , Muscle injection, intraperitoneal injection), ointment, patch, gel, cream, external powder, spray, inhalation spray and the like.
- the preparation containing the quinoline carboxamide derivative of the present invention or a salt thereof can be prepared by a generally known method using a pharmacologically acceptable carrier.
- a pharmacologically acceptable carrier include various general-purpose carriers such as excipients, binders, disintegrants, lubricants, diluents, solubilizers, suspending agents, isotonic agents, pH. Examples thereof include regulators, buffers, stabilizers, colorants, flavoring agents, and odorants.
- Excipients include, for example, lactose, sucrose, sodium chloride, glucose, maltose, mannitol, erythritol, xylitol, maltitol, inositol, dextran, sorbitol, albumin, urea, starch, calcium carbonate, kaolin, crystalline cellulose, cay.
- examples thereof include acids, methylcellulose, glycerin, sodium alginate, gum arabic and mixtures thereof.
- the lubricant include purified talc, stearate, borax, polyethylene glycol and a mixture thereof.
- binder examples include simple syrup, glucose solution, starch solution, gelatin solution, polyvinyl alcohol, polyvinyl ether, polyvinylpyrrolidone, carboxymethyl cellulose, cellac, methyl cellulose, ethyl cellulose, water, ethanol, potassium phosphate and a mixture thereof.
- disintegrant examples include dried starch, sodium alginate, canten powder, laminarin powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose and mixtures thereof. Can be mentioned.
- Examples of the diluent include water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, and mixtures thereof.
- Examples of the stabilizer include sodium pyrosulfite, ethylenediaminetetraacetic acid, thioglycolic acid, thiolactic acid, and mixtures thereof.
- Examples of the tonicity agent include sodium chloride, boric acid, glucose, glycerin and a mixture thereof.
- Examples of the pH adjuster and buffer include sodium citrate, citric acid, sodium acetate, sodium phosphate and a mixture thereof.
- Examples of the pain-relieving agent include procaine hydrochloride, lidocaine hydrochloride, and mixtures thereof.
- the amount of the quinoline carboxamide derivative of the present invention or a salt thereof in the above preparation can be appropriately set, but in general, the amount of the quinoline carboxamide derivative of the present invention or a salt thereof in the preparation is 0.001 to 5000 mg, preferably 0. .1-1000 mg, more preferably 1-500 mg.
- the dose of the quinoline carboxamide derivative of the present invention or a salt thereof is not particularly limited as long as it exerts an antitumor effect and can effectively treat cancer, and the age, cancer type, stage, and presence / absence of metastasis of the patient are not particularly limited.
- the administration form of the immune checkpoint inhibitor is arbitrary, but intravenous administration is preferable.
- the dose of the immune checkpoint inhibitor per dose is not particularly limited and can be appropriately set depending on the carcinoma, side effects, and the like.
- the dose per dose is preferably 0.001 to 5000 mg, more preferably 0.1 to 2000 mg, and particularly preferably 1 to 1200 mg.
- the immune checkpoint inhibitor may be administered continuously in a single dose or in several divided doses (for example, 2 to 4 doses).
- the dosing interval is also not limited, and may be administered every day, or every few days, weeks, weeks, months, or months. For example, once weekly, once every two weeks, once every three weeks, once every four weeks, once a month, once every three months, or every three to six months.
- a single dose and the like are exemplified.
- the administration schedule of the antitumor agent of the present invention can be appropriately set according to the administration schedule of each immune checkpoint inhibitor.
- a quinoline carboxamide derivative or a salt thereof is administered every day from the first day, and each immune checkpoint is administered.
- the inhibitor is administered on the 3rd day, after which the quinoline carboxamide derivative or its salt is administered daily from the 1st day according to the usage of each immune checkpoint inhibitor, and the immune checkpoint inhibitor is administered on the 8th day.
- Immune checkpoint inhibitors are administered daily from day 1 and immune checkpoint inhibitors are administered daily, followed by usage of each immune checkpoint inhibitor, as appropriate according to the usage of checkpoint inhibitors.
- the quinoline carboxamide derivative or a salt thereof is administered daily from the first day, the immune checkpoint inhibitor is administered on the 28th day, and then the usage of each immune checkpoint inhibitor is appropriately followed. ..
- a quinoline carboxamide derivative or a salt thereof and an immune checkpoint inhibitor are administered in combination to a patient, but the means for providing both agents is not particularly limited. That is, the preparations containing each drug should be provided separately, or each preparation should be packaged in a form suitable for each concomitant administration, together with the package insert describing the usage and dosage of the concomitant use. It may be provided by.
- Anti-PD-1 antibody (anti-mouse PD-1 antibody) was purchased from BioLegend.
- Example 1 Antitumor effect by combined administration of quinoline carboxamide derivative and immune checkpoint inhibitor (1).
- Method (1) Tumor transplantation into mice 6-week-old female BALB / c mice (72 mice) were purchased from Japan SLC and used for experiments after acclimatization for 5 days at the Animal Experiment Center of the University of Shizuoka. The back and ventral sides of BALB / c mice were shaved, and 1 ⁇ 10 6 cells of mouse colon cancer cell line CT26 cells (ATCC) were subcutaneously transplanted into the left and right ventral sides (Day 0). Five days after transplantation, the major axis (mm) and minor axis (mm) of the tumor were measured using a digital caliper (A & D), and the tumor volume was calculated.
- a caliper A & D
- the average of the tumor volumes on the left and right of each individual was calculated, and based on this value, the tumors were divided into 8 groups (9 animals in the group) so that the variation in tumor volume among the individuals in each group would be even.
- Drug administration STX-1159 was orally administered at 40 mg / kg for 5 consecutive days. Specifically, a suspension was prepared using a 0.5% methylcellulose solution (Wako) so as to be 4 mg / mL, and 0.01 mL per 1 g of BALB / c mouse body weight was added to a metal sonde ( ⁇ 0.7 ⁇ 50 mm). , Natsume Seisakusho).
- the administration schedule is the period before the administration of the anti-mouse PD-1 antibody (Day 5 to Day 9), the same period as the administration of the anti-mouse PD-1 antibody (Day 12 to Day 16), or the period after the administration of the anti-mouse PD-1 antibody (Day 19 to Day 23). ).
- the anti-mouse PD-1 antibody was intraperitoneally administered at 50 ⁇ g / mouse three times every other day.
- anti-mouse CD279 (PD-1) (Biolegend) was diluted with PBS (Wako) to prepare 250 ⁇ g / mL, and 200 ⁇ L per BALB / c mouse was prepared with a 29G needle syringe (BD). It was administered intraperitoneally. The administration schedule was Day 12, Day 14, and Day 16.
- 200 ⁇ L of PBS was intraperitoneally administered.
- the specific group composition is described below.
- Example 2 Antitumor effect by combined administration of quinoline carboxamide derivative and immune checkpoint inhibitor (2).
- Method (1) Tumor transplantation into mice 6-week-old female BALB / c mice were purchased from Japan SLC and used for experiments after acclimatization for about 1 week at the University of Shizuoka Animal Experiment Center. The back and ventral sides of BALB / c mice were shaved, and 1 ⁇ 10 6 cells of mouse colon cancer cell line CT26 cells (ATCC) were subcutaneously transplanted into the left and right ventral sides (Day 0). Six days after transplantation, the major axis (mm) and minor axis (mm) of the tumor were measured using a digital caliper (A & D), and the tumor volume was calculated.
- a & D digital caliper
- the average of the tumor volumes on the left and right of each individual was calculated, and based on this value, the tumors were grouped so that the variation in tumor volume among the individuals in each group was even.
- Drug administration STX-1159 was orally administered at 40 mg / kg three times every other day. Specifically, a suspension was prepared using a 0.5% methylcellulose solution (Wako) so as to be 4 mg / mL, and 0.01 mL per 1 g of BALB / c mouse body weight was added to a metal sonde ( ⁇ 0.7 ⁇ 50 mm). , Natsume Seisakusho). The administration schedule was Day6, Day8 and Day10. For individuals in the group not receiving STX-1159, a 0.5% methylcellulose solution was orally administered. The anti-mouse PD-1 antibody was intraperitoneally administered at 50 ⁇ g / mouse three times every 1 or 2 days.
- the anti-mouse PD-1 antibody was intraperitoneally administered at 50 ⁇ g / mouse three times every 1 or 2 days.
- anti-mouse CD279 (PD-1) (Biolegend) was diluted with PBS (Wako) to prepare 250 ⁇ g / mL, and 200 ⁇ L per BALB / c mouse was prepared with a 29G needle syringe (BD). It was administered intraperitoneally. The administration schedule was Day 8, Day 10, and Day 13. For individuals in the group not receiving anti-mouse PD-1 antibody, 200 ⁇ L of PBS was intraperitoneally administered. The specific group composition is described below.
- Example 3 Antitumor effect by combined administration of quinoline carboxamide derivative and immune checkpoint inhibitor (3).
- Method (1) Tumor transplantation into mice 6-week-old female BALB / c mice were purchased from Japan SLC and used for experiments after acclimatization for about 1 week at the University of Shizuoka Animal Experiment Center. The back and ventral sides of BALB / c mice were shaved, and 1 ⁇ 10 6 cells of mouse fibrosarcoma CMS5a was subcutaneously transplanted into the left and right ventral sides (Day 0). Five days after transplantation, the major axis (mm) and minor axis (mm) of the tumor were measured using a digital caliper (A & D), and the tumor volume was calculated.
- a & D digital caliper
- the average of the tumor volumes on the left and right of each individual was calculated, and based on this value, the tumors were grouped so that the variation in tumor volume among the individuals in each group was even.
- Drug administration STX-1159 was orally administered at 40 mg / kg for 5 consecutive days. Specifically, a suspension was prepared using a 0.5% methylcellulose solution (Wako) so as to be 4 mg / mL, and 0.01 mL per 1 g of BALB / c mouse body weight was added to a metal sonde ( ⁇ 0.7 ⁇ 50 mm). , Natsume Seisakusho). The administration schedule was the period before administration of the anti-mouse PD-1 antibody (Day 5 to Day 9). For individuals in the group not receiving STX-1159, a 0.5% methylcellulose solution was orally administered. The anti-mouse PD-1 antibody was intraperitoneally administered at 200 ⁇ g / mouse three times every other day.
- Wako 0.5% methylcellulose solution
- anti-mouse CD279 (PD-1) (Biolegend) was diluted with PBS (Wako) to prepare 1 mg / mL, and 200 ⁇ L per BALB / c mouse was prepared with a 29G needle syringe (BD). It was administered intraperitoneally. The administration schedule was Day 12, Day 14, and Day 16. For individuals in the group not receiving anti-mouse PD-1 antibody, 200 ⁇ L of PBS was intraperitoneally administered. The specific group composition is described below.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
1)下記式(I)で表されるキノリンカルボキサミド誘導体又はその塩を有効成分とし、免疫チェックポイント阻害剤と併用投与される抗腫瘍剤であって、免疫チェックポイント阻害剤の投与前に投与される、抗腫瘍剤。
2)下記式(I)で表されるキノリンカルボキサミド誘導体又はその塩と免疫チェックポイント阻害剤が併用投与される抗腫瘍剤であって、前記キノリンカルボキサミド誘導体又はその塩が免疫チェックポイント阻害剤の投与前に投与される、抗腫瘍剤。
3)前記キノリンカルボキサミド誘導体又はその塩の投与が免疫チェックポイント阻害剤の投与の1日以上前に開始される、1)又は2)の抗腫瘍剤。
4)前記キノリンカルボキサミド誘導体又はその塩の投与が免疫チェックポイント阻害剤の投与の7~2日前に開始される、1)~3)のいずれかの抗腫瘍剤。
5)キノリンカルボキサミド誘導体又はその塩の投与経路が経口投与である、1)~4)のいずれかの抗腫瘍剤。
6)式(I)におけるR1及びR2が同一又は異なって、置換若しくは非置換アリール基又は置換若しくは非置換芳香族複素環基である、1)~5)のいずれかの抗腫瘍剤。
7)式(I)におけるR3、R4、R5及びR6の少なくとも一つの基が水素原子以外の基である、6)の抗腫瘍剤。
8)式(I)におけるR1及びR2におけるアリール基がフェニル基、芳香族複素環基がフリル基である、1)~7)のいずれかの抗腫瘍剤。
9)式(I)におけるR1がフリル基、R2が置換又は非置換フェニル基である、1)~7)のいずれかの抗腫瘍剤。
10)R3、R4、R5及びR6の少なくとも一つの基がトリフルオロメトキシ基である、1)~9)のいずれかの抗腫瘍剤。
11)R4がトリフルオロメトキシ基である、1)~10)のいずれかの抗腫瘍剤。
12)式(I)で表されるキノリンカルボキサミド誘導体がN-[5-(2-フリル)-1,3,4-オキサジアゾール-2-イル]-2-フェニル-6-トリフルオロメトキシ-4-キノリンカルボキサミドである、1)~11)のいずれかの抗腫瘍剤。
13)免疫チェックポイント阻害剤がCTLA-4、PD-1、PD-L1、PD-L2、LAG-3、TIM3、BTLA、B7H3、B7H4、2B4、CD160、A2aR、KIR、VISTA及びTIGITから選択される免疫チェックポイント分子に作用してチェックポイント機能を抑制する物質である、1)~12)のいずれかの抗腫瘍剤。
14)免疫チェックポイント阻害剤がPD-1経路阻害剤である、1)~12)のいずれかの抗腫瘍剤。
15)PD-1経路阻害剤が抗PD-1抗体又は抗PD-L1抗体である、14)の抗腫瘍剤。
16)がんが、非小細胞肺がん、腎細胞がん、ホジキンリンパ腫、頭頸部がん、胃がん、悪性胸膜中皮腫、食道がん、胃食道接合部がん、小細胞がん、膠芽腫、尿路上皮がん、筋層浸潤尿路上皮がん、膀胱がん、筋層非浸潤性膀胱がん、大腸がん、膵がん、前立腺がん、メルケル細胞がん、甲状腺がん、肝細胞がん、乳がん、卵巣がん、子宮体がん、子宮頸がん、軟部肉腫、ウイルス陽性・陰性固形がん、中枢神経原発リンパ腫/精巣原発リンパ腫、MSI-High固形がん、メラノーマ及び白血病から選ばれる1以上である1)~15)のいずれかの抗腫瘍剤。
17)免疫チェックポイント阻害剤と併用投与される抗腫瘍剤であって、免疫チェックポイント阻害剤の投与前に投与される、抗腫瘍剤を製造するための、下記式(I)で表されるキノリンカルボキサミド誘導体又はその塩の使用。
18)がん治療のために、免疫チェックポイント阻害剤と組み合わせて使用され、免疫チェックポイント阻害剤の投与前に投与される、下記式(I)で表されるキノリンカルボキサミド誘導体又はその塩。
19)下記式(I)で表されるキノリンカルボキサミド誘導体又はその塩と免疫チェックポイント阻害剤を患者に有効量投与することを含むがんの治療方法であって、前記キノリンカルボキサミド誘導体又はその塩が免疫チェックポイント阻害剤の投与前に投与される、方法。
ここで、アルキル基における置換基としては、ハロゲン原子、ヒドロキシ基等が挙げられる。また、アリール基、芳香族複素環基における置換基としては、炭素数1~6のアルキル基、アルケニル基、アルキニル基、シクロアルキル基、アラルキル基、ORa、NRbRc、S(O)qRd(式中、qは、0、1又は2を表す)、CORe、COORf、OCORg、CONRhRi、NRjCORk、NRlCOORm、NRnSO2Ro、C(=NRp)NRqRr、NRsSO2NRtRu、SO2NRvRw、ニトロ基、シアノ基及びハロゲン原子等から適宜選択される。ここで、Ra~Rwは、同一又は異なって、水素原子、アルキル基、アルケニル基、アルキニル基、シクロアルキル基等を表してもよい。
これら置換基の置換数としては、同一又は異なって、最大各基に存在する水素原子の数まで可能であるが、好ましくは1~10、より好ましくは1~5である。
アルキル基及びアルコキシ基のアルキル部分としては、例えば、直鎖又は分岐状の炭素数1~12のアルキル、具体的には、メチル、エチル、プロピル、イソプロピル、ブチル、イソブチル、sec-ブチル、tert-ブチル、ペンチル、イソペンチル、ネオペンチル、ヘキシル、ヘプチル、オクチル、ノニル、デシル、ウンデシル、ドデシル等が挙げられる。
またさらに、R3、R5及びR6が水素原子で、R4がOR8(好ましくは、メトキシ基又はトリフルオロメトキシ基)である化合物がより好ましい。
これは、キノリンカルボキサミド誘導体又はその塩を前投与することにより、腫瘍の免疫環境を、免疫チェックポイント阻害剤が効果を発揮する上で好ましい状態、すなわち腫瘍免疫細胞が活性化された状態、腫瘍免疫抑制環境が解除された状態等に整えることができるためと考えられる。したがって、免疫チェックポイント阻害剤を投与しても免疫反応による抗腫瘍効果が十分に得られない腫瘍に対しても、キノリンカルボキサミド誘導体を前投与して腫瘍免疫環境を好ましい状態に整えることにより、免疫チェックポイント阻害剤による抗腫瘍効果が期待できる。
したがって、本発明のキノリンカルボキサミド誘導体又はその塩を免疫チェックポイント阻害剤と組み合わせて使用し、且つキノリンカルボキサミド誘導体又はその塩を免疫チェックポイント阻害剤の投与前に投与することは、効果的ながんの治療方法となり、本発明のキノリンカルボキサミド誘導体又はその塩は、免疫チェックポイント阻害剤と併用投与するための抗腫瘍剤であって、免疫チェックポイント阻害剤の投与前に投与される、抗腫瘍剤となり得る。また、本発明のキノリンカルボキサミド誘導体又はその塩は、免疫チェックポイント阻害剤と併用投与するための抗腫瘍剤であって、免疫チェックポイント阻害剤の投与前に投与される、抗腫瘍剤を製造するために使用できる。
本発明のキノリンカルボキサミド誘導体又はその塩の投与開始時期は、より好ましくは、免疫チェックポイント阻害剤の投与の2日以上前であり、より好ましくは投与の28~2日前、より好ましくは投与の21日~2日前、より好ましくは投与の14~2日前、より好ましくは投与の7~2日前である。
また、本発明のキノリンカルボキサミド誘導体又はその塩の投与は、免疫チェックポイント阻害剤の投与前に開始されていればよく、免疫チェックポイント阻害剤の投与開始後も継続されていても良く、また免疫チェックポイント阻害剤の投与開始前に当該投与が終了或いは休薬されていても良い。
(1)キノリンカルボキサミド誘導体
下記式で示される、N-[5-(2-フリル)-1,3,4-オキサジアゾール-2-イル]-2-フェニル-6-トリフルオロメトキシ-4-キノリンカルボキサミド(以下、「STX-1159」と称する)を、特許文献1に記載の方法に準じて合成した。
抗PD-1抗体(抗マウスPD-1抗体)をBiolegendから購入した。
1.方法(1)マウスへの腫瘍移植
6週齢の雌性BALB/cマウス(72匹)は、日本SLCより購入し、静岡県立大学動物実験センターにて5日間の馴化飼育後、実験に使用した。
BALB/cマウスの背部及び腹側部を剃毛し、左右の腹側部にそれぞれ1×106cellsのマウス大腸がん細胞株CT26細胞(ATCC)を皮下移植した(Day0)。移植から5日後、デジタルノギス(エー・アンド・デイ)を用いて腫瘍の長径(mm)及び短径(mm)を測定し、腫瘍体積を算出した。腫瘍体積の算出式は、腫瘍体積(mm3)=0.5×(長径mm)×(短径mm)2とした。
各個体、左右の腫瘍体積の平均を算出し、この値を基に各群における個体間の腫瘍体積のばらつきが均等になるよう、8群(群内匹数9匹)に群分けした。
STX-1159は、40mg/kgにて5日間連続で経口投与した。具体的には、4mg/mLとなるよう0.5%メチルセルロース溶液(Wako)を用いて懸濁液を調製し、BALB/cマウスの体重1gあたり0.01mLを金属ゾンデ(φ0.7×50mm、夏目製作所)にて経口投与した。投与スケジュールは、抗マウスPD-1抗体投与前の期間(Day5からDay9)、抗マウスPD-1抗体投与と同じ期間(Day12からDay16)または抗マウスPD-1抗体投与後の期間(Day19からDay23)の何れかとした。STX-1159を投与しない群の個体については0.5%メチルセルロース溶液を経口投与した。
抗マウスPD-1抗体は、50μg/mouseにて1日おきに3回腹腔内投与した。具体的には、anti-mouse CD279(PD-1)(Biolegend)をPBS(Wako)にて希釈し250μg/mLに調製、BALB/cマウス1匹あたり200μLを29G針付シリンジ(BD)にて腹腔内投与した。投与スケジュールは、Day12、Day14及びDay16とした。抗マウスPD-1抗体を投与しない群の個体については、200μLのPBSを腹腔内投与した。具体的な群構成は以下に記載した。
2)PD-1 Ab(50μg/mouse i.p. Day12,14,16)
3)STX-1159x5回(40mg/kg p.o. Day5-9)
4)STX-1159x5回(40mg/kg p.o. Day12-16)
5)STX-1159x5回(40mg/kg p.o. Day19-23)
6)STX-1159x5回(40mg/kg p.o. Day5-9)+PD-1 Ab(50μg/mouse i.p. Day12,14,16)
7)STX-1159x5回(40mg/kg p.o. Day12-16)+PD-1 Ab(50μg/mouse i.p. Day12,14,16)
8)STX-1159x5回(40mg/kg p.o. Day19-23)+PD-1 Ab(50μg/mouse i.p. Day12,14,16)
評価項目は、各個体における左右の腫瘍体積の平均とした。Day5より、1日または2日間隔でデジタルノギスを用いて腫瘍の長径(mm)及び短径(mm)を測定し、腫瘍体積を算出した。腫瘍体積の算出式は、腫瘍体積(mm3)=0.5×(長径mm)×(短径mm)2とした。各個体、左右の腫瘍体積の平均を算出した。
薬剤投与による腫瘍体積への影響を評価するため、Control群の評価項目に対する薬剤投与群の評価項目についてt検定を実施した。P<0.05またはP<0.01となった場合、有意な差があるとみなし、薬剤投与による腫瘍体積への影響があると判定した。
結果を図1に示す。
キノリンカルボキサミド誘導体を前投与した群(STX-1159(Day5-9)+PD-1 Ab(Day12,14,16))では、同時投与群(STX-1159(Day12-16)+PD-1 Ab(Day12,14,16))、後投与群(STX-1159(Day19-23)+PD-1 Ab(Day12,14,16))に比べて、遥かに高い抗腫瘍効果が認められた。なお、同時投与群(STX-1159(Day12-16)+PD-1 Ab(Day12,14,16)に至っては、単剤投与群であるPD-1 Ab単剤群(Day12,14,16)、STX-1159単剤群(Day5-9)、STX-1159単剤群(Day12-16)及びSTX-1159単剤群(Day19-23)よりも低い抗腫瘍効果が見られた。
1.方法
(1)マウスへの腫瘍移植
6週齢の雌性BALB/cマウスは、日本SLCより購入し、静岡県立大学動物実験センターにて1週間程度の馴化飼育後、実験に使用した。
BALB/cマウスの背部及び腹側部を剃毛し、左右の腹側部にそれぞれ1×106cellsのマウス大腸がん細胞株CT26細胞(ATCC)を皮下移植した(Day0)。移植から6日後、デジタルノギス(エー・アンド・デイ)を用いて腫瘍の長径(mm)及び短径(mm)を測定し、腫瘍体積を算出した。腫瘍体積の算出式は、腫瘍体積(mm3)=0.5×(長径mm)×(短径mm)2とした。各個体、左右の腫瘍体積の平均を算出し、この値を基に各群における個体間の腫瘍体積のばらつきが均等になるよう群分けした。
STX-1159は、40mg/kgにて1日おきに3回経口投与した。具体的には、4mg/mLとなるよう0.5%メチルセルロース溶液(Wako)を用いて懸濁液を調製し、BALB/cマウスの体重1gあたり0.01mLを金属ゾンデ(φ0.7×50mm、夏目製作所)にて経口投与した。投与スケジュールは、Day6、Day8及びDay10とした。STX-1159を投与しない群の個体については0.5%メチルセルロース溶液を経口投与した。
抗マウスPD-1抗体は、50μg/mouseにて1日または2日おきに3回腹腔内投与した。具体的には、anti-mouse CD279(PD-1)(Biolegend)をPBS(Wako)にて希釈し250μg/mLに調製、BALB/cマウス1匹あたり200μLを29G針付シリンジ(BD)にて腹腔内投与した。投与スケジュールは、Day8、Day10及びDay13とした。抗マウスPD-1抗体を投与しない群の個体については、200μLのPBSを腹腔内投与した。具体的な群構成は以下に記載した。
1)Control
2)STX-1159×3回(40mg/kg p.o. Day6,8,10)
3)PD-1 Ab(50μg/mouse i.p. Day8,10,13)
4)STX-1159×3回(40mg/kg p.o. Day6,8,10)+PD-1 Ab(50μg/mouse i.p. Day8,10,13)
評価項目は、個々の腫瘍体積とした。Day6より、1日から4日間隔でデジタルノギスを用いて腫瘍の長径(mm)及び短径(mm)を測定し、腫瘍体積を算出した。腫瘍体積の算出式は、腫瘍体積(mm3)=0.5×(長径mm)×(短径mm)2とした。
薬剤投与による腫瘍体積への影響を評価するため、Control群の評価項目に対する薬剤投与群の評価項目についてt検定を実施した。P<0.05となった場合、有意な差があるとみなし、薬剤投与による腫瘍体積への影響があると判定した。
結果を図2に示す。
キノリンカルボキサミド誘導体を前投与するキノリンカルボキサミド誘導体と免疫チェックポイント阻害剤の併用投与群(STX-1159(Day6,8,10)+PD-1
Ab(Day8,10,13)では、キノリンカルボキサミド誘導体又は免疫チェックポイント阻害剤の単独投与群に比べて、遥かに高い抗腫瘍効果が認められた。
1.方法
(1)マウスへの腫瘍移植
6週齢の雌性BALB/cマウスは、日本SLCより購入し、静岡県立大学動物実験センターにて1週間程度の馴化飼育後、実験に使用した。
BALB/cマウスの背部及び腹側部を剃毛し、左右の腹側部にそれぞれ1×106cellsのマウス線維肉腫CMS5aを皮下移植した(Day0)。移植から5日後、デジタルノギス(エー・アンド・デイ)を用いて腫瘍の長径(mm)及び短径(mm)を測定し、腫瘍体積を算出した。腫瘍体積の算出式は、腫瘍体積(mm3)=0.5×(長径mm)×(短径mm)2とした。各個体、左右の腫瘍体積の平均を算出し、この値を基に各群における個体間の腫瘍体積のばらつきが均等になるよう群分けした。
STX-1159は、40mg/kgにて5日連続で経口投与した。具体的には、4mg/mLとなるよう0.5%メチルセルロース溶液(Wako)を用いて懸濁液を調製し、BALB/cマウスの体重1gあたり0.01mLを金属ゾンデ(φ0.7×50mm、夏目製作所)にて経口投与した。投与スケジュールは、抗マウスPD-1抗体投与前の期間(Day5からDay9)とした。STX-1159を投与しない群の個体については0.5%メチルセルロース溶液を経口投与した。
抗マウスPD-1抗体は、200μg/mouseにて1日おきに3回腹腔内投与した。具体的には、anti-mouse CD279(PD-1)(Biolegend)をPBS(Wako)にて希釈し1mg/mLに調製、BALB/cマウス1匹あたり200μLを29G針付シリンジ(BD)にて腹腔内投与した。投与スケジュールは、Day12、Day14及びDay16とした。抗マウスPD-1抗体を投与しない群の個体については、200μLのPBSを腹腔内投与した。具体的な群構成は以下に記載した。
1)Control
2)PD-1 Ab(200μg/mouse i.p. Day12、14、16)
3)STX-1159×5回(40mg/kg p.o. Day5-9)
4)STX-1159×5回(40mg/kg p.o. Day5-9)
+PD-1 Ab(200μg/mouse i.p. Day12、14、16)
評価項目は、個々の腫瘍体積とした。Day5より、1日または、2日間隔でデジタルノギスを用いて腫瘍の長径(mm)及び短径(mm)を測定し、腫瘍体積を算出した。腫瘍体積の算出式は、腫瘍体積(mm3)=0.5×(長径mm)×(短径mm)2とした。
薬剤投与による腫瘍体積への影響を評価するため、Control群の評価項目に対する薬剤投与群の評価項目についてt検定を実施した。P<0.05またはP<0.01となった場合、有意な差があるとみなし、薬剤投与による腫瘍体積への影響があると判定した。
結果を図3に示す。
キノリンカルボキサミド誘導体を前投与するキノリンカルボキサミド誘導体と免疫チェックポイント阻害剤の併用投与群(STX-1159(Day5-9)+PD-1 Ab(Day12,Day14,Day16)では、Control群に対して併用群で有意な腫瘍縮小が確認された。PD-1 Ab単独投与群では、Controlに対して有意な腫瘍縮小は確認されず、免疫チェックポイント阻害剤が効きにくいとされるCMS5aに対しても、免疫チェックポイント阻害剤にキノリンカルボキサミド誘導体を併用して投与することで抗腫瘍効果が得られることが認められた。
Claims (19)
- 前記キノリンカルボキサミド誘導体又はその塩の投与が免疫チェックポイント阻害剤の投与の1日以上前に開始される、請求項1又は2記載の抗腫瘍剤。
- 前記キノリンカルボキサミド誘導体又はその塩の投与が免疫チェックポイント阻害剤の投与の7~2日前に開始される、請求項1~3のいずれか1項記載の抗腫瘍剤。
- キノリンカルボキサミド誘導体又はその塩の投与経路が経口投与である、請求項1~4のいずれか1項記載の抗腫瘍剤。
- 式(I)におけるR1及びR2が同一又は異なって、置換若しくは非置換アリール基又は置換若しくは非置換芳香族複素環基である、請求項1~5のいずれか1項記載の抗腫瘍剤。
- 式(I)におけるR3、R4、R5及びR6の少なくとも一つの基が水素原子以外の基である、請求項6記載の抗腫瘍剤。
- 式(I)におけるR1及びR2におけるアリール基がフェニル基、芳香族複素環基がフリル基である、請求項1~7のいずれか1項記載の抗腫瘍剤。
- 式(I)におけるR1がフリル基、R2が置換又は非置換フェニル基である、請求項1~7のいずれか1項記載の抗腫瘍剤。
- R3、R4、R5及びR6の少なくとも一つの基がトリフルオロメトキシ基である、請求項1~9のいずれか1項記載の抗腫瘍剤。
- R4がトリフルオロメトキシ基である、請求項1~10のいずれか1項記載の抗腫瘍剤。
- 式(I)で表されるキノリンカルボキサミド誘導体がN-[5-(2-フリル)-1,3,4-オキサジアゾール-2-イル]-2-フェニル-6-トリフルオロメトキシ-4-キノリンカルボキサミドである、請求項1~11のいずれか1項記載の抗腫瘍剤。
- 免疫チェックポイント阻害剤がCTLA-4、PD-1、PD-L1、PD-L2、LAG-3、TIM3、BTLA、B7H3、B7H4、2B4、CD160、A2aR、KIR、VISTA及びTIGITから選択される免疫チェックポイント分子に作用してチェックポイント機能を抑制する物質である、請求項1~12のいずれか1項記載の抗腫瘍剤。
- 免疫チェックポイント阻害剤がPD-1経路阻害剤である、請求項1~12のいずれか1項記載の抗腫瘍剤。
- PD-1経路阻害剤が抗PD-1抗体又は抗PD-L1抗体である、請求項14記載の抗腫瘍剤。
- がんが、非小細胞肺がん、腎細胞がん、ホジキンリンパ腫、頭頸部がん、胃がん、悪性胸膜中皮腫、食道がん、胃食道接合部がん、小細胞がん、膠芽腫、尿路上皮がん、筋層浸潤尿路上皮がん、膀胱がん、筋層非浸潤性膀胱がん、大腸がん、膵がん、前立腺がん、メルケル細胞がん、甲状腺がん、肝細胞がん、乳がん、卵巣がん、子宮体がん、子宮頸がん、軟部肉腫、ウイルス陽性・陰性固形がん、中枢神経原発リンパ腫/精巣原発リンパ腫、MSI-High固形がん、メラノーマ及び白血病から選ばれる1以上である請求項1~15のいずれか1項記載の抗腫瘍剤。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021516209A JPWO2020218432A1 (ja) | 2019-04-26 | 2020-04-23 | |
EP20795339.9A EP3960199A4 (en) | 2019-04-26 | 2020-04-23 | CANCER POLYTHERAPY USING A QUINOLINE CARBOXAMIDE DERIVATIVE |
AU2020262765A AU2020262765A1 (en) | 2019-04-26 | 2020-04-23 | Immune checkpoint inhibitor combination therapy using quinoline carboxamide derivative |
KR1020217036207A KR20220004664A (ko) | 2019-04-26 | 2020-04-23 | 퀴놀린카르복사미드 유도체를 사용하는 면역 체크 포인트 저해제 병용 요법 |
US17/606,294 US20220218693A1 (en) | 2019-04-26 | 2020-04-23 | Immune checkpoint inhibitor combination therapy using quinoline carboxamide derivative |
CN202080030729.7A CN113747920A (zh) | 2019-04-26 | 2020-04-23 | 使用喹啉甲酰胺衍生物的免疫检查点抑制剂并用疗法 |
CA3138012A CA3138012A1 (en) | 2019-04-26 | 2020-04-23 | Immune checkpoint inhibitor combination therapy using quinoline carboxamide derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-085041 | 2019-04-26 | ||
JP2019085041 | 2019-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020218432A1 true WO2020218432A1 (ja) | 2020-10-29 |
Family
ID=72942147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/017522 WO2020218432A1 (ja) | 2019-04-26 | 2020-04-23 | キノリンカルボキサミド誘導体を用いる免疫チェックポイント阻害剤併用療法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220218693A1 (ja) |
EP (1) | EP3960199A4 (ja) |
JP (1) | JPWO2020218432A1 (ja) |
KR (1) | KR20220004664A (ja) |
CN (1) | CN113747920A (ja) |
AU (1) | AU2020262765A1 (ja) |
CA (1) | CA3138012A1 (ja) |
TW (1) | TW202106300A (ja) |
WO (1) | WO2020218432A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023143611A1 (zh) * | 2022-01-30 | 2023-08-03 | 兰泰克生物技术公司 | 一种治疗癌症的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5650529B2 (ja) | 1974-09-30 | 1981-11-30 | ||
WO2010004761A1 (ja) * | 2008-07-10 | 2010-01-14 | 一般社団法人ファルマIp | キノリンカルボキサミド誘導体を有効成分とするstat3阻害剤 |
JP2017537070A (ja) * | 2014-10-24 | 2017-12-14 | アストラゼネカ アクチボラグ | 組合せ |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019023525A1 (en) * | 2017-07-28 | 2019-01-31 | Dana-Farber Cancer Institute, Inc. | ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS |
EP3854397A4 (en) * | 2018-09-18 | 2022-07-13 | Kabushiki Kaisha Yakult Honsha | CANCER MULTIPLE THERAPY USING A QUINOLINE CARBOXAMIDE DERIVATIVE |
-
2020
- 2020-04-23 EP EP20795339.9A patent/EP3960199A4/en not_active Withdrawn
- 2020-04-23 CN CN202080030729.7A patent/CN113747920A/zh active Pending
- 2020-04-23 AU AU2020262765A patent/AU2020262765A1/en not_active Abandoned
- 2020-04-23 WO PCT/JP2020/017522 patent/WO2020218432A1/ja unknown
- 2020-04-23 KR KR1020217036207A patent/KR20220004664A/ko active Search and Examination
- 2020-04-23 JP JP2021516209A patent/JPWO2020218432A1/ja not_active Withdrawn
- 2020-04-23 CA CA3138012A patent/CA3138012A1/en active Pending
- 2020-04-23 US US17/606,294 patent/US20220218693A1/en active Pending
- 2020-04-24 TW TW109113867A patent/TW202106300A/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5650529B2 (ja) | 1974-09-30 | 1981-11-30 | ||
WO2010004761A1 (ja) * | 2008-07-10 | 2010-01-14 | 一般社団法人ファルマIp | キノリンカルボキサミド誘導体を有効成分とするstat3阻害剤 |
JP2017537070A (ja) * | 2014-10-24 | 2017-12-14 | アストラゼネカ アクチボラグ | 組合せ |
Non-Patent Citations (1)
Title |
---|
See also references of EP3960199A4 |
Also Published As
Publication number | Publication date |
---|---|
US20220218693A1 (en) | 2022-07-14 |
CN113747920A (zh) | 2021-12-03 |
JPWO2020218432A1 (ja) | 2020-10-29 |
CA3138012A1 (en) | 2020-10-29 |
TW202106300A (zh) | 2021-02-16 |
AU2020262765A1 (en) | 2021-12-16 |
KR20220004664A (ko) | 2022-01-11 |
EP3960199A4 (en) | 2023-05-10 |
EP3960199A1 (en) | 2022-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9539245B2 (en) | Combination of immunotherapies with activators of Tie-2 | |
JP2019505578A (ja) | 未成熟終止コドンのリードスルーを促進することにより免疫反応を誘発するための方法 | |
WO2020030016A1 (en) | Combination of immunotherapies with mdm2 inhibitors | |
JP2023165946A (ja) | Ep4阻害剤およびその使用 | |
JP2022516093A (ja) | 癌の治療のための免疫調節薬の組み合わせおよび方法 | |
EP3076963A1 (en) | Combination of aurora kinase inhibitors and anti-cd30 antibodies | |
JP6942726B2 (ja) | クロメン化合物および第2活性薬剤の併用薬 | |
JP2018531278A (ja) | 癌のための併用療法 | |
JP2018531278A6 (ja) | 癌のための併用療法 | |
TW201836610A (zh) | Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案 | |
JP2023509359A (ja) | 鉄依存性細胞分解の誘導物質との併用抗癌療法 | |
JP2021528393A (ja) | 後細胞シグナル伝達因子の調節による免疫活性の上昇 | |
WO2020218432A1 (ja) | キノリンカルボキサミド誘導体を用いる免疫チェックポイント阻害剤併用療法 | |
Zhang et al. | The therapeutic potential of PD-1/PD-L1 pathway on immune-related diseases: based on the innate and adaptive immune components | |
KR20210031633A (ko) | 치료에서의 p2rx7 조절자 | |
WO2020059705A1 (ja) | キノリンカルボキサミド誘導体を用いるがん併用療法 | |
KR102167193B1 (ko) | 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법 | |
JP2020534289A (ja) | がんの治療のための方法および組成物 | |
KR102320885B1 (ko) | 글루타민 수송체 억제제를 유효성분으로 포함하는 면역관문 억제제의 항암 효과 증진용 약학적 조성물 | |
CN115227695A (zh) | 包含靶向治疗剂的联合疗法 | |
US20240229032A1 (en) | Multitargeting RNA Immunotherapy Compositions | |
JP7074760B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
JP2022527345A (ja) | Pd1阻害剤及びil-17b阻害剤に基づく複合療法 | |
CA3177444A1 (en) | Use of ezh2 inhibitors for treating cancer | |
JPWO2020027217A1 (ja) | がんの治療及び/又は予防のための医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20795339 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021516209 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3138012 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020795339 Country of ref document: EP Effective date: 20211126 |
|
ENP | Entry into the national phase |
Ref document number: 2020262765 Country of ref document: AU Date of ref document: 20200423 Kind code of ref document: A |